Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04571892 | A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 58 | Shanghai East HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05171790 | A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors | unknown | Phase 1 | 419 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05801094 | A Phase I Study of QL1604 for Advanced Solid Tumors | unknown | Phase 1 | 71 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05539157 | Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | unknown | Phase 1 | 1 | Immorna Biotherapeutics, Inc.INDUSTRY | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05798546 | Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) | unknown | Phase 1 | 21 | BGI, ChinaOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05785728 | A Study of DB-1202 Monotherapy in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 150 | DualityBio Inc.INDUSTRY | 1 | Mar 31, 2023 | clinicaltrials |
| NCT04522284 | PRECISE CURATE.AI Pilot Clinical Trial | unknown | Phase 1 / Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04053673 | Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors | unknown | Phase 1 | 130 | Ribon Therapeutics, Inc.INDUSTRY | 2 | Mar 28, 2023 | clinicaltrials |
| NCT05775666 | UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors | unknown | Phase 1 | 87 | Peking UniversityOTHER | 0 | Mar 20, 2023 | clinicaltrials |
| NCT05434299 | A Study of TFX05-01 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 36 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05768321 | Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation | unknown | Phase 1 | 70 | GenEros Biopharma Hangzhou LtdINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT04947033 | A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors | unknown | Phase 1 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05759234 | A Study of HS248 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 24 | Hanhui Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05175235 | Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements | unknown | Phase 1 / Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05554666 | A Study of ASKG315 in Patients With Advanced Solid Tumors. | unknown | Phase 1 | 56 | AskGene Pharma, Inc.INDUSTRY | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05748938 | A Study of RD14-01 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 12 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT04768868 | The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors(WEE1) | unknown | Phase 1 | 350 | Impact Therapeutics, Inc.INDUSTRY | 3 | Feb 24, 2023 | clinicaltrials |
| NCT05740215 | Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 158 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04930354 | ECP-1014 Treatment for Patients With Solid Tumor Cancers | unknown | Phase 1 | 29 | Euclises Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05276609 | ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 177 | Shanghai Hansoh Biomedical Co., LtdINDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05537051 | A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours | unknown | Phase 1 | 30 | Biotheus Inc.INDUSTRY | 0 | Feb 8, 2023 | clinicaltrials |
| NCT05706207 | A Study of HB0030 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05584709 | Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors | unknown | Phase 1 | 34 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 30, 2023 | clinicaltrials |
| NCT05234853 | Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors | unknown | Phase 1 | 23 | Purinomia Biotech, Inc.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05537987 | Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | InnoCare Pharma Inc.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT04900519 | Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 100 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05673538 | TT-00973-MS Tablets in Patients With Advanced Solid Tumors | unknown | Phase 1 | 40 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05642949 | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 400 | Minghui Pharmaceutical Pty LtdINDUSTRY | 1 | Jan 9, 2023 | clinicaltrials |
| NCT05666635 | Study of LTC004 in Subjects With Advanced Malignant Tumors | unknown | Phase 1 | 368 | LetolabINDUSTRY | 0 | Dec 28, 2022 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05649761 | A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 61 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT04614740 | The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 115 | Jiangsu vcare pharmaceutical technology co., LTDINDUSTRY | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05644509 | Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor | unknown | Phase 1 | 10 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05645315 | Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 127 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT04433494 | A Study of TY-302 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | TYK Medicines, IncINDUSTRY | 1 | Dec 7, 2022 | clinicaltrials |
| NCT04450901 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Y Biologics Inc.INDUSTRY | 3 | Dec 5, 2022 | clinicaltrials |
| NCT05338957 | A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | unknown | Phase 1 / Phase 2 | 30 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04472858 | A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 30 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05205408 | A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 7 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT04976218 | TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors | unknown | Phase 1 | 30 | Chinese PLA General HospitalOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT03792958 | Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 19 | AnewPharmaINDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05461287 | Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 290 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 10, 2022 | clinicaltrials |
| NCT03774979 | SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors | unknown | Phase 1 | 193 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05609019 | A Study Evaluating SYHX2005 in the Treatment of Patients With Advanced Solid Tumors | unknown | Phase 1 | 139 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT03491631 | Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors | unknown | Phase 1 | 23 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 12, 2023source: clinicaltrials